IRIS UniCatt

Chiloiro, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.579
AS - Asia 3.688
EU - Europa 2.581
SA - Sud America 919
AF - Africa 108
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 11.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.371
SG - Singapore 1.575
BR - Brasile 744
CN - Cina 737
IT - Italia 682
VN - Vietnam 558
DE - Germania 447
SE - Svezia 324
FR - Francia 265
BD - Bangladesh 165
GB - Regno Unito 140
FI - Finlandia 129
JP - Giappone 125
RU - Federazione Russa 110
IE - Irlanda 105
ID - Indonesia 104
IN - India 104
CA - Canada 100
PL - Polonia 90
HK - Hong Kong 85
AR - Argentina 69
UA - Ucraina 69
MX - Messico 61
NL - Olanda 51
ZA - Sudafrica 40
AT - Austria 39
TR - Turchia 31
IQ - Iraq 30
EC - Ecuador 26
ES - Italia 26
KR - Corea 26
BE - Belgio 24
VE - Venezuela 22
PK - Pakistan 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 16
CO - Colombia 16
EG - Egitto 15
CL - Cile 14
IR - Iran 14
UZ - Uzbekistan 12
MA - Marocco 11
PE - Perù 11
PY - Paraguay 11
CI - Costa d'Avorio 9
AL - Albania 8
AZ - Azerbaigian 8
HU - Ungheria 8
JO - Giordania 8
KE - Kenya 8
LT - Lituania 8
PT - Portogallo 8
RO - Romania 8
CH - Svizzera 7
DO - Repubblica Dominicana 7
JM - Giamaica 7
MY - Malesia 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
LK - Sri Lanka 6
MD - Moldavia 6
PH - Filippine 6
RS - Serbia 6
TN - Tunisia 6
HN - Honduras 5
KZ - Kazakistan 5
AU - Australia 4
BS - Bahamas 4
ET - Etiopia 4
GR - Grecia 4
IL - Israele 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AM - Armenia 3
BB - Barbados 3
BG - Bulgaria 3
GE - Georgia 3
KG - Kirghizistan 3
NP - Nepal 3
SN - Senegal 3
BH - Bahrain 2
BO - Bolivia 2
DK - Danimarca 2
DZ - Algeria 2
GT - Guatemala 2
LB - Libano 2
SV - El Salvador 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AQ - Antartide 1
BW - Botswana 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GU - Guam 1
Totale 11.869
Salva come PNG Salva come JPEG
Città #
Singapore 864
San Jose 498
Ashburn 417
Chandler 410
Ho Chi Minh City 209
Rome 206
New York 196
Beijing 166
Los Angeles 142
The Dalles 120
Hanoi 113
Lauterbourg 105
Tokyo 103
Hefei 96
Dublin 92
São Paulo 85
Warsaw 81
Jakarta 80
Milan 79
St Louis 79
Ann Arbor 78
Hong Kong 77
Chicago 73
Munich 72
Moscow 68
Tukwila 68
Fairfield 67
Dallas 65
Frankfurt am Main 65
Helsinki 58
San Mateo 57
Wilmington 52
Boston 49
Council Bluffs 45
Bremen 44
Houston 43
Kent 43
Seattle 43
Orem 41
Cattolica 40
Montreal 40
Turku 40
Marseille 38
Denver 36
Princeton 35
Santa Clara 35
Boardman 34
London 32
Buffalo 31
Da Nang 29
Rio de Janeiro 29
Brooklyn 28
Jacksonville 27
Nanjing 27
Atlanta 25
Nuremberg 24
Brussels 23
Haiphong 22
Seoul 22
Woodbridge 22
Hyderabad 21
Lappeenranta 21
Mexico City 21
Cambridge 20
Johannesburg 20
North Bergen 20
Phoenix 20
Paris 18
Amsterdam 17
Belo Horizonte 17
Stockholm 17
Shanghai 16
Toronto 16
Vienna 16
Chennai 15
Hangzhou 15
Guangzhou 14
Hải Dương 14
Poplar 14
Redmond 14
Augusta 13
Bari 13
Redwood City 13
Baghdad 12
Mountain View 12
Mumbai 12
Porto Alegre 12
Querétaro 12
Thái Nguyên 12
Ankara 11
Bexley 11
Dearborn 11
Manchester 11
Memphis 11
Norwalk 11
Quito 11
Elk Grove Village 10
Goiânia 10
Las Vegas 10
Lawrence 10
Totale 6.462
Salva come PNG Salva come JPEG
Nome #
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 340
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 326
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 307
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 212
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 202
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 174
Xanthogranuloma of the sellar region: A rare tumor. Case illustration and literature review 161
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. 158
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 158
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 151
Temporoparietal Fascia Flap (TPFF) in Extended Endoscopic Transnasal Skull Base Surgery: Clinical Experience and Systematic Literature Review 150
The Changing Clinical Spectrum of Hypophysitis 148
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 148
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 146
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 145
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 145
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 139
Pediatric craniopharyngiomas: magnetic resonance imaging assessment for hypothalamus-pituitary axis dysfunction and outcome prediction 137
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 134
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 133
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 128
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 128
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 127
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 127
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 124
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 120
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 120
Empty sella syndrome: Multiple endocrine disorders. 120
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 120
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 120
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 119
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 118
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 116
Hypothalamitis and pituitary atrophy 115
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 114
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 114
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review 114
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 113
Gut Microbiota, LADA, and Type 1 Diabetes Mellitus: An Evolving Relationship 111
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 110
Acromegaly in the elderly patients 110
Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature 110
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 110
Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors 109
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 109
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 109
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 108
Understanding the effect of acromegaly on the human skeleton. 108
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 108
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 106
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 105
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 105
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 104
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 104
Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview 104
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 101
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 101
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 100
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 98
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 98
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 98
Hypophysitis in COVID-19: a systematic review 97
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 96
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 95
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 95
Empty sella syndrome: an update 92
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 92
Acromegaly can be cured by first-line pasireotide treatment? 92
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 90
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 88
The immune microenviroment in somatotropinomas: from biology to personalized and target therapy 87
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 86
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 86
De-escalation treatment with pasireotide for acromegaly: a long-term experience 85
Artificial Intelligence for Individualized Radiological Dialogue: The Impact of RadioBot on Precision-Driven Medical Practices 84
Reliability of intraoperative visual evoked potentials (iVEPs) in monitoring visual function during endoscopic transsphenoidal surgery 83
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 82
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 81
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 81
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 81
Consensus on criteria for acromegaly diagnosis and remission 81
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 80
Letter: A Multicenter, Propensity Score- Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas 80
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 79
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 79
The Role of Testosterone in Spermatogenesis: Lessons From Proteome Profiling of Human Spermatozoa in Testosterone Deficiency 76
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 76
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 75
Interpretable Machine Learning-Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study 72
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 72
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 72
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 67
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 66
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 65
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 65
Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading 64
Cerebrospinal fluid and serum biomarkers in idiopathic intracranial hypertension: A systematic review 63
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly 63
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 62
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review 61
Totale 11.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.660
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022474 20 11 6 37 76 25 9 85 23 21 54 107
2022/20231.087 132 153 78 190 56 161 61 78 103 19 27 29
2023/2024658 31 121 23 31 35 113 28 10 39 40 85 102
2024/20251.939 37 42 122 81 91 70 38 54 237 193 449 525
2025/20266.984 773 251 483 994 921 348 989 361 380 521 670 293
Totale 12.096